← All trials
NCT07260435
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 20, 2024
- Primary completion
- Nov 30, 2027
- Completion date
- Dec 31, 2027
- First posted
- Dec 3, 2025
- Last posted
- Dec 3, 2025
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Erasmus University RotterdamLead sponsor
- Erasmus University RotterdamSponsor investigator
- Stichting TreatmedsCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.